Trials / Completed
CompletedNCT00129571
Study of XL820 in Adults With Solid Tumors
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL820 |
Timeline
- Start date
- 2005-08-01
- First posted
- 2005-08-12
- Last updated
- 2008-06-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00129571. Inclusion in this directory is not an endorsement.